Melanoma Molecular Maps Projects



Title: List of mTOR inhibitors
Legend: mTOR inhibitors (e.g. AP-23573/deforolimus, CCI-779/temsirolimus, RAD001/everolimus, rapamycin/sirolimus), are being tested as anticancer agents as they block a key downstream component of the PI3K/Akt pathway (i.e. mTOR), which is often upregulated in many cancer types (including melanoma) and promotes different tumor promoting events, such as cell survival and angiogenesis. Currently available mTOR inhibitors bind to FK506 binding protein (FKBP) and along with it they inhibit mTOR (FK506 / tacrolimus also binds to FKBP but then inhibits calcineurin). REFERENCES: [1] Guertin DA et al, Cancer Cell 2007, 12:9-22. [2] Boulay A et al, Recent Results Cancer Res 2007, 172:99-124. [3] Granville CA et al, Clin Cancer Res 2006, 12:679-89.
Author: The MMMP Team (updated: June 2008)

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

NCBI's Disclaimer and Copyright notice